ISRCTN11342830已完成未知
The effect of canagliflozin 300 mg, in subjects without diabetes after bariatric surgery, on glucose homeostasis (the CONTROL study): a proof-of-concept, randomised, open-label, two-period crossover study
niversity of Leicester0 个研究点目标入组 36 人开始时间: 2020年7月24日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Age =18 years old but less than 75 years old
- •2. =1 year after gastric bypass (RYGB) or sleeve gastrectomy (SG)
- •3. Able to understand written and spoken English
- •4. Able to give informed consent
排除标准
- •1. Use of any glucose-lowering medication (including insulin)
- •2. Adrenal insufficiency and/or substitution with glucocorticoids
- •3. ALT > 1.5 times the upper normal limit
- •4. Moderate to severe renal impairment (eGFR< = 60 ml/min/1.73m2)
- •5. Individuals on loop diuretics
- •6. Participants with established diagnosis of postural hypotension by their GP
- •7. Recent active infection (over the last 10 days)
- •8. Current use of steroids
- •9. Other bariatric procedure except RYGB/SG
- •10. Previous revisional bariatric surgery
- •11. Currently pregnant or breastfeeding
- •12. Females of child-bearing age, unwilling to use contraception during the period of the study
- •13. Patients with history of Type 1 or Type 2 diabetes
- •14. Intolerant to the Mixed Meal Tolerance test
- •15. HbA1C > = 6.5% or > = 48mmol/l at screening blood tests
- •16. Haemoglobin (Hb) < 100 g/L at screening blood tests
- •17. Clinical contraindication to Canagliflozin
- •18. Known osteoporosis
- •19. Previous history of Fournier’s gangrene
- •20. History of epilepsy
- •21. Known foot ulcers/previous amputation
- •22. Participating in another research study involving intervention within 3 months of screening
- •23. Having a formal previous diagnosis of postprandial hypoglycaemia
- •24. Being on acarbose, diazoxide, octreotide or other treatment for postprandial hypoglycaemia
- •25. Participants without established previous diagnosis of postprandial hyperinsulinaemic hypoglycaemia but with symptoms suggestive of frequent (defined as more than once weekly) AND severe postprandial hypoglycaemia at the screening hypoglycaemia questionnaire (severe is defined as at least two symptoms on Edinburgh Hypoglycaemia Scale (EHS) Questionnaire with intensity > 5 in a scale from 1 to 7) over the last 2 months
研究者
相似试验
进行中（未招募）
1 期
The effect of canagliflozin 300mg on glucose levels in people without diabetes after weight loss surgery.EUCTR2019-004041-32-GBniversity of Leicester24
已完成
不适用
Study of the beneficial effect of Canagliflozin on nocturnal home BP in Japanese T2DM patients(SHIFT-J STUDY)Type 2 diabetes mellitus patients with hypertensionJPRN-UMIN000023487Jichi Medical University School of Medicine100
尚未招募
不适用
Canagliflozin in non diabetic proteinuric diseaseCTRI/2020/09/027679COMMAND HOSPITAL AIR FORCE BANGALORE
尚未招募
不适用
Effect of canagliflozin as an alternative drug from DPP-4 inhibitor on heart failure with diabetis melltus : the pilot study "Can canagliflozin HAve Not only hypoGlycemic but cardiac supportive Effect?"chronic heart failure with type 2 diabetis mellitusJPRN-UMIN000031563Osaka Rosai Hospital40
已完成
不适用
Effect of SGLT2 inhibitor, canagliflozin, for the size of lipid particlesType 2 diabetesJPRN-UMIN000020027Tokyo Medical and Dental University Department of Medical Genetics / Gerontorgy30